Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04757116 · ClinicalTrials.gov registry record · NA

Post-Market Study to Assess iTind Safety in Comparison to UroLift

A NA study of Benign Prostatic Hyperplasia (BPH), sponsored by Olympus Corporation of the Americas.

Recruiting
Registry status
NA
Development phase
206
Enrollment target
18
Study locations

NCT04757116: Recruiting NA study of Benign Prostatic Hyperplasia (BPH), sponsored by Olympus Corporation of the Americas.

NCT04757116 is a NA study of Benign Prostatic Hyperplasia (BPH) that is actively recruiting participants, run by Olympus Corporation of the Americas. The registered enrollment target is 206 participants, above the 45-participant average among 3 other Benign Prostatic Hyperplasia (BPH) trials with a reported enrollment target (358% higher). The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04757116, a NA study of Benign Prostatic Hyperplasia (BPH), is actively recruiting participants, sponsored by Olympus Corporation of the Americas.

RECRUITING
Registry status
NA
Development phase
206 participants
Enrollment target
18
Study locations

Study Summary

The study objective is to evaluate the safety of the iTind device comparied to UroLift.

Primary Outcome

Difference in change of IPSS from baseline between iTind and UroLift groups at 3 months

Interventions

  • DEVICE iTind
  • PROCEDURE UroLift

Study Locations (18)

Texas

  • Midtown Urology Associates - Austin
  • Houston Metro Urology - Houston
  • The Urology Place - San Antonio

Other

  • Queen Margaret Hospital - Dunfermline
  • Frimley Park Hospital - London
  • Norfolk & Norwich University Hospital - Norwich

Arizona

  • Mayo Clinic Arizona - Phoenix
  • Arizona Urology Specialists - Tucson

California

  • Urology Associates of Central California - Fresno
  • Golden State Urology - Sacramento

Illinois

  • NorthShore University Health System Research Institute - Evanston

Louisiana

  • Southeast Louisiana Veterans Health Care System - New Orleans

Minnesota

  • Minnesota Urology - Woodbury

Nebraska

  • Adult & Pediatric Urology - Omaha

Trial Details

FieldValue
Enrollment Target 206 participants
Start Date 2022-09-26
Est. Completion 2031-12-31
Phase NA

What NCT04757116 shows while recruiting

NCT04757116 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, above the 45-participant average among 3 other Benign Prostatic Hyperplasia (BPH) trials with a reported enrollment target (358% higher).

The record links to 1 condition, with Benign Prostatic Hyperplasia (BPH) appearing as the primary indexed condition, and to 2 interventions - of which iTind is the first listed.

NCT04757116 lists 18 locations in 12 states (Texas, Other, Arizona).

Frequently Asked Questions

What is clinical trial NCT04757116 about?

NCT04757116 is a clinical study titled "Post-Market Study to Assess iTind Safety in Comparison to UroLift". The study objective is to evaluate the safety of the iTind device comparied to UroLift.

What is the current status of trial NCT04757116?

This trial is currently recruiting. It is a NA study. The enrollment target is 206 participants. The study started on 2022-09-26. Estimated completion is 2031-12-31.

What conditions does trial NCT04757116 study?

This clinical trial studies the following conditions: Benign Prostatic Hyperplasia (BPH).

What interventions are being tested in trial NCT04757116?

The interventions under investigation include: iTind (DEVICE), UroLift (PROCEDURE).

Who is sponsoring clinical trial NCT04757116?

This trial is sponsored by Olympus Corporation of the Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04757116 being conducted?

This trial has 18 study locations across Arizona, California, Illinois, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Benign Prostatic Hyperplasia (BPH)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03373968 · 206 participants · Phase 2

    Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

  • NCT03550391 · 206 participants · Phase 3

    Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

  • NCT05675865 · 206 participants · NA

    Cryoablation for Monomorphic Ventricular Tachycardia

  • NCT04353778 · 207 participants · Phase 1

    Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04757116, the US trial registry maintained by the National Library of Medicine. NCT04757116 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.